“CDLK5 Forum Award for Excellence – Company Making a Difference 2023 Pre-clinical” presented by the Loulou Foundation at the CDKL5 Forum, 6th-7th November in London
ConSynance wins FDA designation for Prader-Willi syndrome therapy – Pharmaceutical Technology
CSTI-500 works by increasing the levels of monoamine neurotransmitters in the synaptic cleft. Image credit: Shutterstock / nobeastsofierce. The US Food and Drug Administration (FDA)
July 25, 2024